Clinical trial
Phase I, Open-Label, Multi-Center, Single-Dose, Dose-Escalating, Safety, Tolerability and Pharmacokinetic of GC1008 in Patients With Idiopathic Pulmonary Fibrosis
NCT00125385 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I, Open-Label, Multi-Center, Single-Dose, Dose-Escalating, Safety, Tolerability and Pharmacokinetic of GC1008 in Patients With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2005
- Completion date
- September 30, 2008
- Enrollment
- 25 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.